| 000 | 01641 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250514235114.0 | ||
| 264 | 0 | _c20060622 | |
| 008 | 200606s 0 0 eng d | ||
| 022 | _a1538-4047 | ||
| 024 | 7 |
_a10.4161/cbt.4.10.1995 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRosetti, M | |
| 245 | 0 | 0 |
_aModulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines. _h[electronic resource] |
| 260 |
_bCancer biology & therapy _cOct 2005 |
||
| 300 |
_a1089-95 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xblood |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aCarcinoma _xpathology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aDrug-Related Side Effects and Adverse Reactions |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xblood |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aGefitinib |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMitogen-Activated Protein Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPancreatic Neoplasms _xpathology |
| 650 | 0 | 4 |
_aQuinazolines _xblood |
| 700 | 1 | _aTesei, A | |
| 700 | 1 | _aUlivi, P | |
| 700 | 1 | _aFabbri, F | |
| 700 | 1 | _aVannini, I | |
| 700 | 1 | _aBrigliadori, G | |
| 700 | 1 | _aGranato, A M | |
| 700 | 1 | _aAmadori, D | |
| 700 | 1 | _aZoli, W | |
| 773 | 0 |
_tCancer biology & therapy _gvol. 4 _gno. 10 _gp. 1089-95 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.4161/cbt.4.10.1995 _zAvailable from publisher's website |
| 999 |
_c15720805 _d15720805 |
||